,0
question,Q: How is Bempegaldesleukin supposed to overcome Treg affinity for IL-2?
full_answer,"Bempegaldesleukin overcomes Treg affinity for IL-2 through selective depletion of intratumoral Tregs, thereby enhancing anti-tumor immune responses. This targeted approach allows the agent to effectively stimulate an immune response against tumors while minimizing suppression by regulatory T cells."
answer_letter,B
ground_truth,Preferentially binding to b2b3 complex over b1b2b3 complex
result,1
timestamp,2024-12-09 21:19:10
